RT Journal Article
SR Electronic
T1 Biallelic and <em>de novo</em> variants in <em>ATP6V0A1</em> cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21257500
DO 10.1101/2021.06.01.21257500
A1 Laura C Bott
A1 Mitra Forouhan
A1 Maria Lieto
A1 Ambre J Sala
A1 Ruth Ellerington
A1 Janel O Johnson
A1 Alfina A Speciale
A1 Chiara Criscuolo
A1 Alessandro Filla
A1 David Chitayat
A1 Andrea H Nemeth
A1 Italian Undiagnosed Diseases Network
A1 Francesco Angelucci
A1 Wooi Fang Lim
A1 Pasquale Striano
A1 Federico Zara
A1 Ingo Helbig
A1 Mikko Muona
A1 Carolina Courage
A1 Anna-Elina Lehesjoki
A1 Samuel F Berkovic
A1 V-ATPase Consortium
A1 Kenneth H Fischbeck
A1 Francesco Brancati
A1 Richard I Morimoto
A1 Matthew JA Wood
A1 Carlo Rinaldi
YR 2021
UL http://medrxiv.org/content/early/2021/06/07/2021.06.01.21257500.abstract
AB The vacuolar H+-ATPase is a large multi-subunit proton pump, composed of an integral membrane V0 domain, involved in proton translocation, and a peripheral V1 domain, catalysing ATP hydrolysis. This complex is widely distributed on the membrane of various subcellular organelles, such as endosomes and lysosomes, and plays a critical role in cellular processes ranging from autophagy to protein trafficking and endocytosis. Variants in ATP6V0A1, the brain-enriched isoform in the V0 domain, have been recently associated with developmental delay and epilepsy in four individuals. Here we identified 17 individuals from 14 unrelated families with both with new and previously characterised variants in this gene, representing the largest cohort to date. Five affected subjects with biallelic variants in this gene presented with a phenotype of early-onset progressive myoclonus epilepsy with ataxia, while 12 individuals carried de novo missense variants and showed severe developmental and epileptic encephalopathy. The R740Q mutation, which alone accounts for almost 50% of the mutations identified among our cases, leads to failure of lysosomal hydrolysis by directly impairing acidification of the endolysosomal compartment, causing autophagic dysfunction and severe developmental defect in C. elegans. Altogether, our findings further expand the neurological phenotype associated with variants in this gene and provide a direct link with endolysosomal acidification in the pathophysiology of ATP6V0A1-related conditions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll funding support in the present work is disclosed in the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the ethics committee of the following institutes: University of Federico II (Italy), University of L Aquila (Italy), G. Gaslini Institute (Italy), University of Exeter (UK), Nottingham University Hospital (UK), Salpetriere Hospital (France), University of Toronto (Canada), University of Ottawa (Canada), St. Luke s Children's Hospital (USA), Floating Hospital for Children at Tufts Medical Center (USA), Gillette Children s Specialty Healthcare Children's Hospital (USA), Children s Hospital of Philadelphia (USA), Peking University First Hospital, Beijing (China). Written consent for the study was obtained from patients or legal representatives according to the Declaration of Helsinki. When individuals were not contacted directly, de-identified phenotypic and genomic data were used. Patient or guardian consent was given for the publication of the patient s data and clinical information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.